Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29280 | 0.71 | MEN1 (0.33) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL5613285 | 0.65 | ALDH1A1 (0.32) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL5500863 | 0.64 | — | — | |
| SCHEMBL9958734 | 0.64 | GRK6 (0.34) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL330550 | 0.64 | GRK6 (0.34) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL9958738 | 0.64 | GRK6 (0.34) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL2903859 | 0.64 | GRK6 (0.34) | MEN1USP2PPARGKMT2AKEAP1 | |
| Hydrochloric Acid SCHEMBL7477355 | 0.62 | GRK6 (0.33) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL27344588 | 0.62 | GRK6 (0.33) | MEN1USP2PPARGKMT2AKEAP1 | |
| Hydrochloric Acid SCHEMBL5739950 | 0.62 | GRK6 (0.33) | MEN1USP2PPARGKMT2AKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3325497-B1 | QUINSTATIN COMPOUNDS | UNIV ARIZONA STATE (US) | 2020-09-02 | — | — | EP | claimed |
| US-10435435-B2 | Quinstatin compounds | THE ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-08 | — | — | US | claimed |
| US-20180371012-A1 | QUINSTATIN COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-12-27 | — | — | US | claimed |
| EP-3325497-A1 | QUINSTATIN COMPOUNDS | Pettit, George, Robert (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017019489-A1 | QUINSTATIN COMPOUNDS | PETTIT GEORGE ROBERT (US) | 2017-02-02 | — | — | WO | claimed |
| EP-3325497-B1 | QUINSTATIN COMPOUNDS | UNIV ARIZONA STATE (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10435435-B2 | Quinstatin compounds | THE ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180371012-A1 | QUINSTATIN COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-12-27 | — | — | US | disclosed |
| EP-3325497-A1 | QUINSTATIN COMPOUNDS | Pettit, George, Robert (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017019489-A1 | QUINSTATIN COMPOUNDS | PETTIT GEORGE ROBERT (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | MEN1 726/4885USP2 3813/4885PPARG 2621/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885USP2 3878/4885PPARG 3563/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885USP2 3878/4885PPARG 3563/4885 |
| US-10435435-B2 | Quinstatin compounds | QTRT1, COQ8A, QPCT | MEN1 2987/4885USP2 1866/4885PPARG 2902/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MEN1 457/4885USP2 3878/4885PPARG 3563/4885 |
| US-20180371012-A1 | QUINSTATIN COMPOUNDS | QTRT1, COQ8A, QPCT | MEN1 2987/4885USP2 1866/4885PPARG 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.